Načítá se...
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
Low-dose metronomic chemotherapy is a promising therapeutic cancer treatment strategy thought to have an antiangiogenic basis. However, the advantages of reduced toxicity, increased efficacy in some cases, and ability to combine chemotherapy administered long term in this way with targeted therapies...
Uloženo v:
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
The American Society of Hematology
2005
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1895327/ https://ncbi.nlm.nih.gov/pubmed/15998832 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-04-1422 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|